AVEO has built a pipeline of proprietary inducible in vivo cancer models for Target Discovery and Human Response Prediction. These tissue-specific models are engineered to contain genetic mutations present in human disease.
Our Platform >

07/22/2008
   Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement
   Read More >

05/29/2008
   AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma
   Read More >

05/22/2008
   AVEO Pharmaceuticals Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets
   Read More >

AVEO is developing a pipeline of targeted therapies which address major unmet medical needs in the field of oncology. The two lead products; AV-951 and AV-412, are in phases II and I, respectively.
Our Products >